Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home

Sebastiano Mercadante, Alessandra Casuccio, Antonio Agnello, Roberto Serretta, Luciano Calderone, Luca Barresi

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

Purpose: The aim of this study was to evaluate the analgesic and adverse effects and the doses of methadone in comparison to morphine. Patients and Methods: A prospective randomized study was performed in a sample of 40 patients with advanced cancer who required strong opioids for their pain management. Patients were treated with sustained-release morphine or methadone in doses titrated against the effect administered two or three times daily according to clinical need. Opioid doses, adjuvant medications, symptoms associated with opioid therapy, pain intensity, and pain mechanisms were recorded. The opioid escalation indices in percentage (OEI%) and milligrams (OEImg) were calculated. The effective analgesic score (EAS) that monitors the analgesic consumption-pain ratio was also calculated at fixed weekly intervals. Results: differences in pain intensity were found. Patients treated with methadone reported values of OEI significantly less than those observed in patients treated with morphine. Seven patients in the methadone group maintained the same initial dosage until death, whereas only one patient in the morphine group did not require opioid dose escalation. A more stable analgesia in time in patients treated with methadone was shown by the low number of gaps in EASs reported. Symptom frequencies and intensities were similar in the two groups. Conclusion: Methadone is a drug of indisputable value in the treatment of cancer pain, and an unbalanced focus on the risks of inappropriate use rather than the benefits should not compromise the use of a relevant alternative to morphine in the management of cancer pain.

Original languageEnglish
Pages (from-to)3656-3661
Number of pages6
JournalJournal of Clinical Oncology
Volume16
Issue number11
Publication statusPublished - Nov 1998

Fingerprint

Methadone
Morphine
Pain
Opioid Analgesics
Neoplasms
Analgesics
Therapeutics
Pain Management
Analgesia
Prospective Studies
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Mercadante, S., Casuccio, A., Agnello, A., Serretta, R., Calderone, L., & Barresi, L. (1998). Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home. Journal of Clinical Oncology, 16(11), 3656-3661.

Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home. / Mercadante, Sebastiano; Casuccio, Alessandra; Agnello, Antonio; Serretta, Roberto; Calderone, Luciano; Barresi, Luca.

In: Journal of Clinical Oncology, Vol. 16, No. 11, 11.1998, p. 3656-3661.

Research output: Contribution to journalArticle

Mercadante, S, Casuccio, A, Agnello, A, Serretta, R, Calderone, L & Barresi, L 1998, 'Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home', Journal of Clinical Oncology, vol. 16, no. 11, pp. 3656-3661.
Mercadante S, Casuccio A, Agnello A, Serretta R, Calderone L, Barresi L. Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home. Journal of Clinical Oncology. 1998 Nov;16(11):3656-3661.
Mercadante, Sebastiano ; Casuccio, Alessandra ; Agnello, Antonio ; Serretta, Roberto ; Calderone, Luciano ; Barresi, Luca. / Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home. In: Journal of Clinical Oncology. 1998 ; Vol. 16, No. 11. pp. 3656-3661.
@article{d6bbe2f0582d46028ee9d059f075dba7,
title = "Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home",
abstract = "Purpose: The aim of this study was to evaluate the analgesic and adverse effects and the doses of methadone in comparison to morphine. Patients and Methods: A prospective randomized study was performed in a sample of 40 patients with advanced cancer who required strong opioids for their pain management. Patients were treated with sustained-release morphine or methadone in doses titrated against the effect administered two or three times daily according to clinical need. Opioid doses, adjuvant medications, symptoms associated with opioid therapy, pain intensity, and pain mechanisms were recorded. The opioid escalation indices in percentage (OEI{\%}) and milligrams (OEImg) were calculated. The effective analgesic score (EAS) that monitors the analgesic consumption-pain ratio was also calculated at fixed weekly intervals. Results: differences in pain intensity were found. Patients treated with methadone reported values of OEI significantly less than those observed in patients treated with morphine. Seven patients in the methadone group maintained the same initial dosage until death, whereas only one patient in the morphine group did not require opioid dose escalation. A more stable analgesia in time in patients treated with methadone was shown by the low number of gaps in EASs reported. Symptom frequencies and intensities were similar in the two groups. Conclusion: Methadone is a drug of indisputable value in the treatment of cancer pain, and an unbalanced focus on the risks of inappropriate use rather than the benefits should not compromise the use of a relevant alternative to morphine in the management of cancer pain.",
author = "Sebastiano Mercadante and Alessandra Casuccio and Antonio Agnello and Roberto Serretta and Luciano Calderone and Luca Barresi",
year = "1998",
month = "11",
language = "English",
volume = "16",
pages = "3656--3661",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "11",

}

TY - JOUR

T1 - Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home

AU - Mercadante, Sebastiano

AU - Casuccio, Alessandra

AU - Agnello, Antonio

AU - Serretta, Roberto

AU - Calderone, Luciano

AU - Barresi, Luca

PY - 1998/11

Y1 - 1998/11

N2 - Purpose: The aim of this study was to evaluate the analgesic and adverse effects and the doses of methadone in comparison to morphine. Patients and Methods: A prospective randomized study was performed in a sample of 40 patients with advanced cancer who required strong opioids for their pain management. Patients were treated with sustained-release morphine or methadone in doses titrated against the effect administered two or three times daily according to clinical need. Opioid doses, adjuvant medications, symptoms associated with opioid therapy, pain intensity, and pain mechanisms were recorded. The opioid escalation indices in percentage (OEI%) and milligrams (OEImg) were calculated. The effective analgesic score (EAS) that monitors the analgesic consumption-pain ratio was also calculated at fixed weekly intervals. Results: differences in pain intensity were found. Patients treated with methadone reported values of OEI significantly less than those observed in patients treated with morphine. Seven patients in the methadone group maintained the same initial dosage until death, whereas only one patient in the morphine group did not require opioid dose escalation. A more stable analgesia in time in patients treated with methadone was shown by the low number of gaps in EASs reported. Symptom frequencies and intensities were similar in the two groups. Conclusion: Methadone is a drug of indisputable value in the treatment of cancer pain, and an unbalanced focus on the risks of inappropriate use rather than the benefits should not compromise the use of a relevant alternative to morphine in the management of cancer pain.

AB - Purpose: The aim of this study was to evaluate the analgesic and adverse effects and the doses of methadone in comparison to morphine. Patients and Methods: A prospective randomized study was performed in a sample of 40 patients with advanced cancer who required strong opioids for their pain management. Patients were treated with sustained-release morphine or methadone in doses titrated against the effect administered two or three times daily according to clinical need. Opioid doses, adjuvant medications, symptoms associated with opioid therapy, pain intensity, and pain mechanisms were recorded. The opioid escalation indices in percentage (OEI%) and milligrams (OEImg) were calculated. The effective analgesic score (EAS) that monitors the analgesic consumption-pain ratio was also calculated at fixed weekly intervals. Results: differences in pain intensity were found. Patients treated with methadone reported values of OEI significantly less than those observed in patients treated with morphine. Seven patients in the methadone group maintained the same initial dosage until death, whereas only one patient in the morphine group did not require opioid dose escalation. A more stable analgesia in time in patients treated with methadone was shown by the low number of gaps in EASs reported. Symptom frequencies and intensities were similar in the two groups. Conclusion: Methadone is a drug of indisputable value in the treatment of cancer pain, and an unbalanced focus on the risks of inappropriate use rather than the benefits should not compromise the use of a relevant alternative to morphine in the management of cancer pain.

UR - http://www.scopus.com/inward/record.url?scp=0031764050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031764050&partnerID=8YFLogxK

M3 - Article

C2 - 9817288

AN - SCOPUS:0031764050

VL - 16

SP - 3656

EP - 3661

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 11

ER -